Immunocytochemical detection of breast cancer cells in marrow and peripheral blood of patients undergoing high dose chemotherapy with autologous stem cell support

Breast Cancer Research and Treatment

Volumn 41, Issue 1, 1996, Pages 1-13

  Franklin, Wilbur A ^a   Shpall, Elizabeth J ^a   Archer, Philip ^a   Johnston, Charles S ^a   Garza Williams, Sara ^a   Hami, Lisa ^a   Bitter, Mitchell A ^a   Bast, Robert C ^b   Jones, Roy B ^a  

^a UNIVERSITY OF COLORADO   (United States)

^b UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

Bone marrow; Breast neoplasms; Immunohistochemistry; Monoclonal antibodies; Transplantation

Indexed keywords

4 HYDROXYCYCLOPHOSPHAMIDE; CD34 ANTIGEN; DOXORUBICIN; FLUOROURACIL; GLYCOPROTEIN; HEMATOXYLIN; METHOTREXATE; MONOCLONAL ANTIBODY;

ARTICLE; BONE MARROW; BREAST CANCER; CANCER STAGING; CELL COUNT; CELL SELECTION; CONTROLLED STUDY; FEMALE; HUMAN; HUMAN CELL; IMMUNOCYTOCHEMISTRY; MAJOR CLINICAL STUDY; MALE; MONONUCLEAR CELL; PERIPHERAL BLOOD STEM CELL; PRIORITY JOURNAL; PROBABILITY; STEM CELL TRANSPLANTATION;

ANTIBODIES, MONOCLONAL; ANTIGENS, CD34; ANTIGENS, NEOPLASM; ANTINEOPLASTIC AGENTS; BONE MARROW; BREAST NEOPLASMS; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; IMMUNOHISTOCHEMISTRY; NEOPLASM CIRCULATING CELLS; NEOPLASM METASTASIS; TRANSPLANTATION, AUTOLOGOUS;

EID: 0029823584     PISSN: 01676806     EISSN: None     Source Type: Journal    
DOI: 10.1007/BF01807031     Document Type: Article

References (43)

1. Peters WP, Shpall EJ, Jones RB et al.: High-dose combination alkylating agents with bone marrow support as initial treatment for metastatic breast cancer. J Clin Oncol 6: 1368-1375, 1988
2. Peters WP, Davis R, Shpall EJ et al.: Adjuvant chemotherapy involving high-dose combination cyclophosphamide, cisplatin, carmustine (CPA/CDDP/BCNU with bone marrow support for stage II/II breast cancer involving ten or more lymph nodes (CALGB 8782): A preliminary report. Proc Am Soc Clin Oncol 9: 22, 1990 (abstr)
3. Kennedy MJ, Beveridge RA, Rowley SD, Gordon GB, Abeloff MD, Davidson NE: High-dose chemotherapy with reinfusion of purged autologous bone marrow following dose-intense induction as initial therapy for metastatic breast cancer. J Natl Cancer Inst 83: 920-926, 1991
4. Vincent MD, Powles TJ, Coombes RC, McElwain TJ: Late intensification with high-dose melphalan and autologous bone marrow support in breast cancer patients responding to conventional chemotherapy. Cancer Chemother Pharmacol 21: 255-260, 1988
5. Dunphy FR, Spitzer G, Buzdar AU et al.: Treatment of estrogen receptor-negative or hormonally refractory breast cancer with double high-dose chemotherapy intensification and bone marrow support. J Clin Oncol 8: 1207-1216, 1990
6. Williams SF, Mick R, Desser R, Golick J, Beschorner J, Bitran JD: High-dose consolidation therapy with autologous stem cell rescue in stage IV breast cancer. J Clin Oncol 7: 1824-1830, 1989
7. Hortobagyi GN: Bone metastases in breast cancer patients. Sem Oncol 18 (Suppl 5): 11-15, 1991
8. Tubiana-Hulin M: Incidence, prevalence and distribution of bone metastases. Bone 12 (Suppl 1): S9-S10, 1991
9. Sharp J, Kessinger A, Mann S: Detection and clinical significance of minimal tumor cell contamination of peripheral blood stem cell harvest. Int J Cell Cloning 10: 92-94, 1992
10. Brugger W, Bross KJ, Glatt B, Georgi F, Mertelsmann R. Kanz L: Mobilization of tumor cells and hematopoietic progenitor cells into peripheral blood of patients with solid tumors. Blood 83: 636-640, 1994
11. Shpall EJ, Jones RB, Bast RC et al.: 4-Hydroperoxycyclophosphamide purging of breast cancer from the mononuclear cell fraction of bone marrow in patients receiving high-dose chemotherapy and autologous marrow support: a phase I trial. J Clin Oncol 9: 85-93, 1991
12. Vredenburgh JJ, Shpall EJ, Ross M et al.: Immunopharmacologic bone marrow purging and high dose chemotherapy with autologous bone marow support (ABMS) for patients with metastatic breast cancer. Proc Am Soc Clin Oncol 11:58, 1992 (abstr)
13. Shpall EJ, Bast RC, Joines WT et al.: Immunomagnetic purging of breast cancer from bone marrow for autologous transplantation. Bone Marrow Transplant 7: 145-151, 1991
14. Shpall EJ, Jones RB, Johnston C et al.: WR-2721 (Amifostine) shortens the engraftment period of 4-hydroperoxycyclophosphamide (4-HC) purged bone marrow patients receiving high-dose chemotherapy with autologous bone marrow support (ABMS). Blood 78 (Suppl 1): 192a, 1991 (abstr)
15. Shpall EJ, Jones RB, Franklin WA et al.: Transplantation of enriched CD34-positive autologous marrow into breast cancer patients following high-dose chemotherapy: Influence of CD34+ peripheral blood progenitors and growth factors on engraftment. J Clin Oncol 12: 28-36, 1994
16. Leslie DS, Johnston WW, Daly L et al.: Detection of breast carcinoma cells in human bone marrow using fluorescence-activated cell sorting and conventional cytology. Am J Clin Pathol 94: 8-13, 1990
17. Molino A, Colobatti M, Bonetti F et al.: A comparative analysis of three different techniques for the detection of breast cancer cells in bone marrow. Cancer 67: 1033-1036, 1991
18. Joshi SS, Novak DJ, Messbarger L, Maitreyan V, Weisenburger DD, Sharp JG: Levels of detection of tumor cells in human bone marrow with or without prior culture. Bone Marrow Transplant 6: 179-183, 1990
19. Vaughn WP, Mann SL, Garvey J et al.: Breast cancer detected in cell culture of histologically negative bone marrow predicts systemic relapse in patients with stage I, II, III and locally recurrent disease. Proc Am Soc Clin Oncol 9: 9, 1990 (abstr)
20. Gribben JC, Freedmen AS, Neuberg D et al.: Immunologic purging of marrow assessed by PCR before autologous bone marrow transplantation for B-cell lymphoma. New Engl J Med 325: 1525-1533, 1991
21. Yuan R, Dowling P, Zucca E et al.: Detection of bcl-2/JH rearrangement in follicular and diffuse lymphoma: concordant results of peripheral blood and bone marrow analysis at diagnosis. Br J Cancer 67: 922-925, 1993
22. Sloane J, Ormerod MC, Neville AM: Potential pathological application of immunocytochemical methods to the detection of micrometastases. Cancer Res 40: 3079-3082, 1980
23. Dearnaley DP, Sloane JP, Ormerod MG et al.: Increased detection of mammary carcinoma cells in marrow smears using antisera to epithelial membrane antigen. Br J Cancer 44: 85-90, 1981
24. Schlimok G, Funke I, Holzmann B et al.: Micrometastatic cancer cells in bone marrow: In vitro detection with anticytokeratin and in vivo labeling with anti-17-1A monoclonal antibodies. Proc Natl Acad Sci USA 84: 8672-8676, 1987
25. Cote RJ, Rosen PP, Hakes TB et al.: Monoclonal antibodies detect occult breast carcinoma metastases in the bone marrow of patients with early stage disease. Am J Surg Pathol 12: 333-340, 1988
26. Osborne MP, Wong GY, Asina S, Old LJ, Cote RJ, Rosen PP: Sensitivity of immunocytochemical detection of breast cancer cells in human bone marrow. Cancer Res 51: 2706-2709, 1991
27. Osborne MP, Rosen PP: Detection and management of bone marrow micrometastases in breast cancer. Oncol 8: 25-31, 1994
28. Mansi JL, Berger U, Easton D et al.: Micrometastases. Br Med J 295: 1093-1096, 1987
29. Cote RJ, Rosen PP, Lesser ML, Old LJ, Osborne MP: Prediction of early relapse in patients with operable breast cancer by detection of occult bone marrow micrometastases. J Clin Oncol 9: 1749-1756, 1991
30. Passos-Coelho J, Ross AA, Davis JM, Huelskamp A-M, Clarke B, Noga SJ, Davidson NE, Kennedy MJ: Bone marrow micrometastasis in chemotherapy-responsive advanced breast cancer: Effect of ex vivo purging with 4-hydroxycyclophosphamide. Cancer Res 54: 2266-2371, 1994
31. Ross AA, Cooper BW, Lazarus HM et al.: Incidence of tumor cell contamination in peripheral blood stem cell (PBSC) collections from breast cancer patients. Proc Am Soc Clin Oncol 12: 69 (77), 1993
32. Sharp JC, Kessinger A, Mann S: Detection and clinical significance of minimal tumor cell contamination of peripheral blood stem cell harvests. Intl J Cell Clon 10 (Suppl 1): 92-92, 1992
33. Frankel AE, Ring DB, Tringale F, Hsieh-Ma ST: Tissue distribution of breast cancer-associated antigens defined by monoclonal antibodies. J Biol Response Mod 4: 273-286, 1985
34. Boyer CM, Borowitz MJ, McCarty KS et al.: Heterogeneity of antigen expression in benign and malignant breast and ovarian epithelial cells. Int J Cancer 43: 55-60, 1989
35. Peterson JA, Zava DT, Duwe AK, Blank EW, Battifora H, Ceriani RL: Biochemical and histological characterization of antigens preferentially expressed on the surface and cytoplasm of breast carcinoma cells identified by monoclonal antibodies against the human milk fat globule. Hybridoma 9: 221-235, 1990
36. Stahel RA, Gilks WR, Lehmann H-P, Schenker T: Third International Workshop on Lung Tumor and Differentiation Antigens: Overview of the results of the central data analysis. Int J Cancer 8: 6-26, 1994
37. Fogh J, Wright WC, Loveless JD: Absence of HeLa cell contamination in 169 cell lines derived from human tumors. J Natl Cancer Inst 58: 209-213, 1977
38. Stein H, Gatter K, Asbahr H, Mason DY: Use of freeze-dried paraffin-embedded sections for immunohislologic staining with monoclonal antibodies. Lab Invest 52: 676-683, 1985
39. Snedecor GW, Cochran WG: Statistical Methods. Iowa State University Press, Ames, Iowa, USA, Eighth Edition, 1989, p 200
40. ibid: Regression, pp 177-190
41. ibid: Fitting a straight line through the origin, pp 174-176
42. Jones RB, Shpall EJ, Shogan J et al.: The Duke AFM program. Intensive induction chemotherapy for metastatic breast cancer. Cancer 66: 431-436, 1990
43. Ngan BY, Nourse J, Cleary ML: Detection of chromosomal translocation t(14;18) within the minor cluster region of bcl-2 by polymerase chain reaction and direct genomic sequencing of the enzymatically amplified DNA in follicular lymphomas. Blood 73: 1759-1762, 1989